Etofylline

Etofylline (7- (β-Hydroxyethyl) theophylline) is an oral bronchodilator with anti-inflammatory effects. Etofylline inhibits phosphodiesterase and prevents the degradation of cAMP (cyclic adenosine monophosphate), leading to smooth muscle relaxation, reducing inflammatory responses and improving respiratory function. Etofylline affects the development of zebrafish embryos[1][2][3].

Product Specifications

CAS Number

[519-37-9]

Product Name Alternative

7- (β-Hydroxyethyl) theophylline

UNSPSC

12352005

Hazard Statement

H302

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Etofylline.html

Concentration

10mM

Purity

99.72

Solubility

DMSO : 25 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(N1C)N(C)C2=C(N(CCO)C=N2)C1=O

Molecular Formula

C9H12N4O3

Molecular Weight

224.22

Precautions

H302

References & Citations

[1]Wattanaporn Tavipatana, et al.Etophylline and theophylline pharmacokinetics when administered concomitantly in rabbits. International Journal of Pharmaceutics. Volume 30, Issues 2–3|[2]Chandrakantsing V Pardeshi , et al. Mannose-anchored N, N, N-trimethyl chitosan nanoparticles for pulmonary administration of etofylline. Int J Biol Macromol. 2020 Dec 15;165 (Pt A) :445-459.|[3]Ram Manohar Basnet, et al. Zebrafish Embryo as an In Vivo Model for Behavioral and Pharmacological Characterization of Methylxanthine Drugs. Int J Mol Sci. 2017 Mar 9;18 (3) :596.